Login / Signup

Exploring Heterogeneity in Cost-Effectiveness Using Machine Learning Methods: A Case Study Using the FIRST-ABC Trial.

Zaid HattabEdel DohertyZia SadiquePadmanabhan RamnarayanStephen O'Neill
Published in: Medical care (2024)
The estimated overall INB of HFNC is smaller than the INB for patients with better baseline status suggesting that HFNC can be more cost-effective among less severely ill patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • clinical trial
  • prognostic factors
  • single cell
  • study protocol
  • patient reported outcomes
  • patient reported